

## ■ Preoperative and postoperative care of patients after MitraClip and TriClip procedures: modern approaches and best practices

**id Lucija Karamatić**

Zagreb, Zagreb, Croatia

**KEYWORDS:** minimally invasive procedures, mitral regurgitation, tricuspid regurgitation, quality of life.

**CITATION:** Cardiol Croat. 2025;20(11-12):293. | <https://doi.org/10.15836/ccar2025.293>

\***ADDRESS FOR CORRESPONDENCE:** Ivana Branilović, Klinički bolnički centar Zagreb, Kišpatićeva 12, HR-10000 Zagreb, Croatia. / Phone: +385-1-236-7491 / E-mail: [ivana.martinovic20@gmail.com](mailto:ivana.martinovic20@gmail.com)

**ORCID:** Ivana Branilović, <https://orcid.org/0000-0001-7773-5599> • Monika Radić, <https://orcid.org/0009-0006-1663-9855>  
Lucija Karamatić, <https://orcid.org/0009-0005-1271-323X>

MitraClip and TriClip are minimally invasive percutaneous procedures used to treat mitral and tricuspid regurgitation<sup>1</sup>. MitraClip addresses severe mitral regurgitation, while TriClip targets tricuspid regurgitation. Both interventions reduce blood backflow through the affected valves and improve cardiac function. These procedures are particularly beneficial for patients who are not candidates for conventional surgery, offering reduced invasiveness, shorter recovery, and lower risk of complications<sup>1</sup>.

Preoperative care involves detailed medical history, laboratory and diagnostic tests, cardiac function assessment, and psychological preparation. Special attention is given to anesthesiologic evaluation and the placement of venous catheters. Postoperative care begins with intensive care unit monitoring, including vital signs, therapy administration, and observation for complications such as arrhythmia, bleeding, or infections. After stabilization, patients return to the cardiology ward for continued monitoring of valve function, intervention site care, and therapy. Early mobilization is initiated within 24 hours, and outpatient follow-up and therapy continue after discharge.

These minimally invasive procedures significantly improve patients' quality of life, reduce symptoms, prolong survival, and represent a modern, safe, and effective approach to the treatment of valvular heart disease.

**RECEIVED:**  
**October 1, 2025**

**ACCEPTED:**  
**October 22, 2025**



## LITERATURE |||||||

1. Adamo M, Chioncel O, Benson L, Shahim B, Crespo-Leiro MG, Anker SD, et al. Prevalence, clinical characteristics and outcomes of heart failure patients with or without isolated or combined mitral and tricuspid regurgitation: An analysis from the ESC-HFA Heart Failure Long-Term Registry. *Eur J Heart Fail*. 2023 Jul;25(7):1061-1071. <https://doi.org/10.1002/ejhf.2929>